ASCO Opposes Mandatory Demo for Oncology in Drug Pricing Proposal, Raises Concerns on Reviving CAP
As part of the Trump Administration’s continuing effort to address the cost of prescription drugs, CMS recently solicited input on a proposed new pilot program to test mechanisms for reducing drug costs. The International Pricing Index Model (IPI) for Medicare Part B drugs proposes sweeping reforms that would, in part, benchmark some Medicare Part B drug prices against other countries and change how providers get paid for administering drugs to patients.
On December 31, 2018, ASCO provided feedback to CMS Administrator Seema Verma highlighting the role physicians play in assuring the most appropriate utilization of cancer drug treatments and cautioning against implementing any strategies to contain costs that may limit patient access to care.
For more, please visit ASCO in Action.